No description available.

In this study, effect of cold stress on physiology and biochemistry of two Turkish barley cultivars, winter type Tarm-92 and spring type Zafer-160, was studied. For chilling stress treatment, cultivars were exposed to +4 &ordm / C for 1, 3 and 7 days, and for freezing stress application acclimated cultivars (+4 &ordm / C for 3 days) were treated with -3 &ordm / C and -7 &ordm / C. After freezing stress treatment, a recovery period was applied for 4 days at 4 &ordm / C. Following analyses were performed on leaf and root tissues: growth parameters (length, wet-dry weights), malondialdehyde (MDA) content, proline content, hydrogen peroxide content (H2O2) electrolyte leakage, PS II fluorescence (Fv/Fm), antioxidant enzyme activities such as catalase (CAT: EC 1.11.1.6), ascorbate peroxidase (APX: EC 1.11.1.11) and glutathione reductase (GR: EC 1.6.4.2). It was observed that effect of cold was more at freezing temperatures than chilling temperature. Cold dependent damage was more obvious as the duration of chilling temperature increased. Growth retardation, membrane damage, leaf catalase deactivation were more apparent and leaf glutathione reductase activity increase was less in spring type cultivar Zafer than in winter type Tarm. These results indicated that winter type barley cultivar is more cold tolerant than spring type barley.

Hibridiniai baltymai, koduojami sulietų lamB ir lacZ genų susiriša su išvirkščiomis E.coli ląstelių plazminės membranos pūslelėmis. Sąveika su plazmine membrane priklauso nuo geno secA produkto buvimo. Hibridinių baltymų susirišimas su membrana priklauso nuo išorinės membranos baltymo LamB polipeptidinės grandinės ilgio. Aktyviosios deguonies formos, susidariusios fotosensibilizuojant eukariotų ląsteles lipofiliniu sensibilizatoriumi sukelia membranų pažaidas, padidina lipidų peoksidacijos lygį ir laktato dehidrogenazės išėjimą iš ląstelių. Vidinių ląstelių pažaidos sumažina ląstelių oksidoreduktazių aktyvumą ir ATP kiekį. Aktyviųjų deguonies formų susidarymas mitochondrijų vidinėje ertmėje buvo indukuotas rodaminu arba safraninu. Oksidacinio streso, sukelto mitochondrijų viduje, poveikis skyrėsi nuo įvairių ląstelės membranų fotopažaidų. Ląstelės atsakas į oksidacinį stresą mitochondrijų viduje priklausė nuo poveikio dozės. Pažaidos iki CD50 nesukėlė žymaus ląstelės gyvybingumo sumažėjimo. Didesnės fotopažaidos virš CD70 indukavo apoptozę, aktyvino kaspazę-3 ir iniciavo citochromo išėjimą iš mitochondrijų. / Hybrid proteins encoded by the fused lamB and lacZ genes were able to reconstitute to the membrane of the inside-out vesicles. The reconstitution of the cytoplasmic membrane vesicles was shown to be dependent on the gene sec A product. The interaction of the hybrid proteins with the membranes depended on the length of the LamB polypeptide chain. Production of ROS after photosensibilization with the lipophylic photosensitizer induced the damage to the cell membranes, enhanced lipid peroxidation and resulted in the leakage of lactate dehydrogenase from the cells. The damage of the inner cell membranes induced the decrease of the activity of cell oxidoreductases and the amount of ATP. For the stimulated production of ROS in the inner space of mitochondria, rhodamine123- and safranin-mediated photodynamic treatment was employed. Cell response to the oxidative insult in the mitochondrial interior was different from the response to the photodamage produced in other cellular membranes. Cell response to the oxidative stress in the mitochondrial interior was dose dependent. Damage up to CD50 did not reveal hallmarks of dead cells. Severe damage (beyond CD70) induced apoptosis following release of cytochrome c and caspase activation.

As fosfolipases A2 (PLA2s, ou fosfatidil-acil hidrolases EC 3.1.1.4) catalisam especificamente a hidrólise das ligações ácido-éster na posição sn-2 de glicerofosfolipídios liberando, como produto da catálise, ácidos graxos e lisofosfolipídio. São encontradas em plantas, mamíferos e em veneno de animais vertebrados e invertebrados e estão envolvidas em uma ampla variedade de processos fisiológicos. A fosfolipase A2 secretada humana do grupo IIA (hsPLA2 gIIA) é uma proteína de fase aguda da resposta imunológica, pois sua expressão é induzida por endotoxinas e citocinas via processos autócrinos e/ou parácrinos durante processos inflamatórios de relevância clínica. A hsPLA2 gIIA mostra efeito bactericida contra infecção por Staphylococcus aureus, e tem marcada preferência por fosfolipídios aniônicos tais como fosfatidilglicerol (PG) encontrados em membranas bacterianas. Uma grande variedade de inibidores de PLA2 do grupo IIA foi descrita na literatura, incluindo substâncias polianiônicas que atuam contra os efeitos inflamatórios destas enzimas. Suramina é um derivado de naftiluréia polissulfonado que recentemente mostrou ligação com os resíduos catiônicos no sítio de reconhecimento interfacial de Bothropstoxina-I (BthTX-I), uma PLA2-Lys49 isolada do veneno de Bothrops jararacussu, inibindo a atividade miotóxica da proteína. Devido ao tipo de interação diferenciada da suramina com BthTX-I em relação aos inibidores competitivos de PLA2, nós avaliamos a especificidade de ligação da suramina na hsPLA2 gIIA como um modelo para estudar este novo tipo de inibidor de PLA2s. O efeito da suramina nas atividades biológicas e de membranas artificiais da hsPLA2 gIIA foi avaliado. A suramina aboliu tanto a atividade hidrolítica da hsPLA2 gIIA quanto a atividade de danificação de membranas artificiais Ca2+ independente. Embora a suramina não tenha inibido a atividade bactericida da hsPLA2 gIIA contra a linhagem Micrococcus luteus, a ativação de macrófagos foi abolida pela mesma de maneira dependente de hidrólise. Além disso, técnicas de simulação de dinâmica molecular, calorimetria de titulação isotérmica e mutagênese sítio dirigida foram utilizadas para mapear os sítios de ligação da suramina na proteína. A interação da suramina com a hsPLA2 gIIA resultou de interações eletrostáticas entre grupos sulfonados com cadeias laterais de aminoácidos da região do sítio ativo e dos resíduos em torno das posições 15 e 116 localizados, respectivamente, na N- e Cterminal. Portanto, estes resultados permitem sugerir que a suramina pode atuar como inibidor de sPLA2s / Suramin is a polysulphonated napthylurea used as an antiprotozoal drug that presents inhibitory activity against a broad range of enzymes. We have evaluated the effect of suramin against the artificial and biological activities of the secreted human group IIA phospholipase A2 (hsPLA2 gIIA), a protein involved in inflammatory processes. To map the suramin binding sites on the hsPLA2 gIIA, proteins with mutations in the active site region and in the protein surface that makes contact with the phospholipids membrane were expressed in E. coli and refolded from inclusion bodies. The activation of macrophage cell line RAW 264.7 by hsPLA2 gIIA was monitored by nitric oxide release, and bactericidal activity of the protein against Micrococcus luteus was evaluated by colony counting and by flow cytometry. The hydrolytic activity of the hsPLA2 gIIA against lipossomes composed of a mixture of dioleoylphosphatidylcholine/dioleoylphosphatidylglycerol (DOPC/DOPG) was inhibited by a concentration of 100 nM suramin. The activation of macrophages by hsPLA2 gIIA was abolished at protein/suramin molar ratios where the hydrolytic activity of the enzyme was inhibited. In contrast, both the bactericidal activity of hsPLA2 gIIA against Micrococcus luteus and permeabilization of the bacterial inner membrane were unaffected by suramin concentrations up to 50 M. The affinity of interaction of the suramin with hsPLA2 gIIA was evaluated by suramine fluorescence and the mutants K15A, K38A, R54A and K123A presented a reduced affinity. The binding of the suramin/hsPLA2 gIIA complex was investigated by molecular dynamics simulations, which indicated two conformations of the bound inhibitor, which involve cationic amino-acid side chains in the active-site region and residues around positions 15 and 116 located in the N- and C-termini respectively in the substrate recognition surface. These results were correlated with isothermal titration calorimetry data, which demonstrated 2.7 suramin-binding sites on the hsPLA2 gIIA. These results suggested that suramin represents a novel class of phospholipase A2 inhibitor

As fosfolipases A2 (PLA2s, ou fosfatidil-acil hidrolases EC 3.1.1.4) catalisam especificamente a hidrólise das ligações ácido-éster na posição sn-2 de glicerofosfolipídios liberando, como produto da catálise, ácidos graxos e lisofosfolipídio. São encontradas em plantas, mamíferos e em veneno de animais vertebrados e invertebrados e estão envolvidas em uma ampla variedade de processos fisiológicos. A fosfolipase A2 secretada humana do grupo IIA (hsPLA2 gIIA) é uma proteína de fase aguda da resposta imunológica, pois sua expressão é induzida por endotoxinas e citocinas via processos autócrinos e/ou parácrinos durante processos inflamatórios de relevância clínica. A hsPLA2 gIIA mostra efeito bactericida contra infecção por Staphylococcus aureus, e tem marcada preferência por fosfolipídios aniônicos tais como fosfatidilglicerol (PG) encontrados em membranas bacterianas. Uma grande variedade de inibidores de PLA2 do grupo IIA foi descrita na literatura, incluindo substâncias polianiônicas que atuam contra os efeitos inflamatórios destas enzimas. Suramina é um derivado de naftiluréia polissulfonado que recentemente mostrou ligação com os resíduos catiônicos no sítio de reconhecimento interfacial de Bothropstoxina-I (BthTX-I), uma PLA2-Lys49 isolada do veneno de Bothrops jararacussu, inibindo a atividade miotóxica da proteína. Devido ao tipo de interação diferenciada da suramina com BthTX-I em relação aos inibidores competitivos de PLA2, nós avaliamos a especificidade de ligação da suramina na hsPLA2 gIIA como um modelo para estudar este novo tipo de inibidor de PLA2s. O efeito da suramina nas atividades biológicas e de membranas artificiais da hsPLA2 gIIA foi avaliado. A suramina aboliu tanto a atividade hidrolítica da hsPLA2 gIIA quanto a atividade de danificação de membranas artificiais Ca2+ independente. Embora a suramina não tenha inibido a atividade bactericida da hsPLA2 gIIA contra a linhagem Micrococcus luteus, a ativação de macrófagos foi abolida pela mesma de maneira dependente de hidrólise. Além disso, técnicas de simulação de dinâmica molecular, calorimetria de titulação isotérmica e mutagênese sítio dirigida foram utilizadas para mapear os sítios de ligação da suramina na proteína. A interação da suramina com a hsPLA2 gIIA resultou de interações eletrostáticas entre grupos sulfonados com cadeias laterais de aminoácidos da região do sítio ativo e dos resíduos em torno das posições 15 e 116 localizados, respectivamente, na N- e Cterminal. Portanto, estes resultados permitem sugerir que a suramina pode atuar como inibidor de sPLA2s / Suramin is a polysulphonated napthylurea used as an antiprotozoal drug that presents inhibitory activity against a broad range of enzymes. We have evaluated the effect of suramin against the artificial and biological activities of the secreted human group IIA phospholipase A2 (hsPLA2 gIIA), a protein involved in inflammatory processes. To map the suramin binding sites on the hsPLA2 gIIA, proteins with mutations in the active site region and in the protein surface that makes contact with the phospholipids membrane were expressed in E. coli and refolded from inclusion bodies. The activation of macrophage cell line RAW 264.7 by hsPLA2 gIIA was monitored by nitric oxide release, and bactericidal activity of the protein against Micrococcus luteus was evaluated by colony counting and by flow cytometry. The hydrolytic activity of the hsPLA2 gIIA against lipossomes composed of a mixture of dioleoylphosphatidylcholine/dioleoylphosphatidylglycerol (DOPC/DOPG) was inhibited by a concentration of 100 nM suramin. The activation of macrophages by hsPLA2 gIIA was abolished at protein/suramin molar ratios where the hydrolytic activity of the enzyme was inhibited. In contrast, both the bactericidal activity of hsPLA2 gIIA against Micrococcus luteus and permeabilization of the bacterial inner membrane were unaffected by suramin concentrations up to 50 M. The affinity of interaction of the suramin with hsPLA2 gIIA was evaluated by suramine fluorescence and the mutants K15A, K38A, R54A and K123A presented a reduced affinity. The binding of the suramin/hsPLA2 gIIA complex was investigated by molecular dynamics simulations, which indicated two conformations of the bound inhibitor, which involve cationic amino-acid side chains in the active-site region and residues around positions 15 and 116 located in the N- and C-termini respectively in the substrate recognition surface. These results were correlated with isothermal titration calorimetry data, which demonstrated 2.7 suramin-binding sites on the hsPLA2 gIIA. These results suggested that suramin represents a novel class of phospholipase A2 inhibitor

No description available.

Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis, is one of the leading causes of death due to a single infectious agent and results in more than 1 million human deaths every year. M.tb infection of the host initiates a local inflammatory response, resulting in the migration of a number of host plasma protein and non-protein factors to the site of infection. In addition, some of these factors are also produced locally at the site of infection. It is envisaged that these host factors are likely to come in direct contact with M.tb and immune cells and may modulate the outcome of the infection. In this study, a number of host factors including transferrin, lactoferrin, fibrinogen, C-reactive protein, alpha-2-macroglobulin (α2M), vitronectin, plasminogen, low-density lipoprotein (LDL), high-density lipoprotein (HDL), serotonin, L-alpha dipalmitoyl phosphatidylcholine (DPPC) and platelet activating factor C-16 (PAF C-16) were screened in vitro for their direct effect on the growth of mycobacteria using M.smegmatis as a model. As a result of this screening, PAF C-16, a phospholipid compound was identified that directly inhibited the growth of M.smegmatis and M.bovis BCG in a dose and time-dependent manner. Use of a range of PAF C-16 structural analogues, including Lyso-PAF, PAF C-18, Hexanolamino PAF, 2-O-methyl PAF & Pyrrolidino PAF, revealed that small modifications in structure did not alter the direct growth inhibition property of PAF C-16 and similar levels of M.smegmatis and M.bovis BCG growth inhibition were observed as compared to PAF C-16. Structural dissection of PAF C-16 suggested that the attachment of carbon tail to the glycerol backbone via ether bond at sn-1 position was important for its direct growth inhibition activity against mycobacteria. Microscopy and flow cytometry with PAF C-16 treated M.smegmatis and M.bovis BCG showed damage to the bacterial cell membrane. The addition of membrane-stabilizing agents, α-tocopherol, tween-80 and tween-20, partially mitigated the growth inhibitory effect of PAF C-16. These results suggested that the growth inhibition activity of PAF C-16 against mycobacteria is most likely due to its detergent-like effect, resulting in damage to the bacterial cell membrane. PAF C-16 and its structural analogues were also investigated for their effect on the growth of intracellular M.smegmatis inside THP1 cells. In vitro, PAF C-16, PAF C-18 and Hexanolamino PAF inhibited the growth of intracellular M.smegmatis, whereas, analogues such as Lyso-PAF and 2-O-methyl PAF failed to show any growth inhibitory effect, suggesting that the presence of acetyl group at sn-2 position was important for growth inhibition of intracellular M.smegmatis. Use of PAF receptor antagonists partially mitigated the inhibitory effect of PAF C-16 on the growth of intracellular M.smegmatis, suggesting this inhibition was through receptor-mediated signalling pathways. Blocking of PAF C-16 signalling pathway components such as phospholipase C and phospholipase A2, resulted in the increased survival of intracellular M.smegmatis. Arachidonic acid, a product of PAF C-16 signalling pathway directly inhibited the growth of M.smegmatis. Furthermore, inhibition of iNOS enzyme and antibody-mediated neutralization of TNF-α partially mitigated the inhibitory effect of PAF C-16 on intracellular M.smegmatis growth, suggesting that the production of NO and TNF-α were also involved in PAF C-16 induced intracellular growth inhibition. Overall, this study has identified PAF C-16, its structural analogues such as Lyso-PAF, PAF C-18, Hexanolamino PAF and other compounds including 1-O-hexadecyl-sn-glycerol, miltefosine and hexadecyl lactate with novel anti-mycobacterial activity. Further investigations are needed to demonstrate their effectiveness against M.tb both in vitro and in animal models to assess their therapeutic potential as anti-TB drugs.

No description available.